Can I read 682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer on EtoBox?

682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer by M. Tuthill; F. Cappuccini; L. Carter; E. Pollock; I. Poulton; C. Verrill; T. Evans; S. Gillessen; G. Attard; A. Protheroe; F. Hamdy; A.V.S. Hill; I. Redchenko is a Medicine article available to read on EtoBox.

What is 682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer about?

Background: New therapeutic antigen-specific approaches are required to generate and sustain therapeutic immune responses against tumour specific antigens in men with advanced prostate cancer. We have previously reported efficacy data on a novel vaccine based on two replication-deficient viruses, chimpanzee adenovirus (ChAdOx1) and MVA, targeting an oncofetal self-antigen 5T4, administered as a single agent and in combination with anti-PD-1 in mouse tumour models. Based on encouraging safety and exceptional T cell immunogenicity of the VANCE study (NCT02390063), the phase I/II trial, ADVANCE (NCT03815942) was undertaken to test the vaccine safety and efficacy in combination with PD-1 blockade in metastatic castrate-resistant prostate cancer (mCPRC). Methods: ADVANCE recruited mCRPC patients with disease progression on antiandrogen therapy with either enzalutamide or abiraterone. Patients received 2 cycles of ChAdOx1-MVA 5T4 (VTP-800) vaccination and three nivolumab infusions. The primary endpoint is a composite response rate measured as either a 50% reduction of circulating tumour DNA or a 50% serum PSA decrease from baseline at 24-week assessment and the maximal response rate. Sec

Who reads 682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer?

Author

M. Tuthill; F. Cappuccini; L. Carter; E. Pollock; I. Poulton; C. Verrill; T. Evans; S. Gillessen; G. Attard; A. Protheroe; F. Hamdy; A.V.S. Hill; I. Redchenko

Publisher

Oxford University Press; Elsevier BV (ISSN 0923-7534)

Published

2020

Language

EN

Field

Medicine (Health Sciences)